Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Sep;47(9):2971-3.
doi: 10.1128/AAC.47.9.2971-2973.2003.

Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis

Annika Krüüner  1 , Pontus Jureen, Klavdia Levina, Solomon Ghebremichael, Sven Hoffner
Affiliations

Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis

Annika Krüüner et al. Antimicrob Agents Chemother. 2003 Sep.

Abstract

It is generally thought that there is full cross-resistance in Mycobacterium tuberculosis between the aminoglycoside drugs kanamycin and amikacin. However, kanamycin resistance and amikacin susceptibility were seen in 43 of 79 (54%) multidrug-resistant Estonian isolates, indicating that there might be a need to test the resistance of M. tuberculosis isolates to both drugs.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Restriction fragment length polymorphism (RFLP) patterns and resistance to AK and KM of 49 isolates of M. tuberculosis originating from different patients and their mutations in the partially sequenced rrs gene. ID, identification number.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alangaden, G. J., B. N. Kreiswirth, A. Aouad, M. Khetarpal, F. R. Igno, E. K. Manavathu, and S. A. Lerner. 1998. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42:1295-1297. - PMC - PubMed
    1. Ayvazian, L. F. 1993. Tuberculosis—a comprehensive international approach, p. 1-20. In L. B. Reichman and E. S. Hershfield (ed.), History of tuberculosis. Marcel Dekker, Inc., New York, N.Y.
    1. Böttger, E. C. 1994. Resistance to drugs targeting protein synthesis in mycobacteria. Trends Microbiol. 2:416-421. - PubMed
    1. Dobner, P., G. Bretzel, S. Rüsch-Gerdes, K. Feldmann, M. Rifai, T. Löscher, and H. Rinder. 1997. Geographic variation of the predictive values of genomic mutations associated with streptomycin resistance in Mycobacterium tuberculosis. Mol. Cell. Probes 11:123-126. - PubMed
    1. Espinal, M. A., A. Laszlo, L. Simonsen, F. Boulahbal, S. J. Kim, A. Reniero, S. Hoffner, H. L. Rieder, N. Binkin, C. Dye, R. Williams, and M. C. Raviglione. 2001. Global trends in resistance to antituberculosis drugs. N. Engl. J. Med. 344:1294-1303. - PubMed

Publication types

MeSH terms